Disposable eyelid-warming device for the treatment of meibomian gland dysfunction

Asako Mori, Jun Shimazaki, Shigeto Shimmura, Hiroshi Fujishima, Yoshihisa Oguchi, Kazuo Tsubota

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: To assess the clinical efficacy of a newly developed disposable eyelid-warming device (Eye Warmer) for the treatment of meibomian gland dysfunction (MGD). Methods: The Eye Warmer was applied for 5 minutes to 44 eyes of 22 patients who exhibited decreased tear break-up time (BUT) and dry-eye symptoms. Its efficacy was assessed on the basis of BUT and dry-eye symptoms in the short-term study. In the therapeutic study, the Eye Warmer was applied to 34 eyes of 17 MGD patients with decreased BUT and dry-eye symptoms for 5 minutes once a day for 2 weeks. The 16 eyes of 8 patients served as untreated controls. We examined tear film lipid layer interference patterns, BUT, meibomian gland secretion, and dry-eye symptoms in both groups before and after the treatment. Results: BUT and dry-eye symptoms significantly improved after the treatment in both the short-term and the therapeutic study (P<.01). The incidence of normal tear lipid layer in the treated group was significantly higher after treatment (28 eyes [82.4%]) than before (19 eyes [55.9%]) (P=.036). The incidence of meibomian gland obstruction was significantly decreased after treatment (14 eyes [41.2%]) compared to before treatment (26 eyes [76.5%]) (P=.006). Conclusions: Warming the eyelids with the Eye Warmer improved the stability and uniformity of the tear lipid layer in MGD patients by melting the meibomian gland lipid. Our study demonstrates the usefulness of the Eye Warmer for the treatment of MGD.

Original languageEnglish
Pages (from-to)578-586
Number of pages9
JournalJapanese Journal of Ophthalmology
Volume47
Issue number6
DOIs
Publication statusPublished - 2003 Nov

Fingerprint

Meibomian Glands
Eyelids
Equipment and Supplies
Tears
Therapeutics
Lipids
Incidence
Freezing

Keywords

  • Meibomian gland dysfunction
  • Tear film
  • Temperature
  • Warm compress

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Disposable eyelid-warming device for the treatment of meibomian gland dysfunction. / Mori, Asako; Shimazaki, Jun; Shimmura, Shigeto; Fujishima, Hiroshi; Oguchi, Yoshihisa; Tsubota, Kazuo.

In: Japanese Journal of Ophthalmology, Vol. 47, No. 6, 11.2003, p. 578-586.

Research output: Contribution to journalArticle

Mori, Asako ; Shimazaki, Jun ; Shimmura, Shigeto ; Fujishima, Hiroshi ; Oguchi, Yoshihisa ; Tsubota, Kazuo. / Disposable eyelid-warming device for the treatment of meibomian gland dysfunction. In: Japanese Journal of Ophthalmology. 2003 ; Vol. 47, No. 6. pp. 578-586.
@article{75ea1a9324ab42c7a522fa0ae0a777db,
title = "Disposable eyelid-warming device for the treatment of meibomian gland dysfunction",
abstract = "Purpose: To assess the clinical efficacy of a newly developed disposable eyelid-warming device (Eye Warmer) for the treatment of meibomian gland dysfunction (MGD). Methods: The Eye Warmer was applied for 5 minutes to 44 eyes of 22 patients who exhibited decreased tear break-up time (BUT) and dry-eye symptoms. Its efficacy was assessed on the basis of BUT and dry-eye symptoms in the short-term study. In the therapeutic study, the Eye Warmer was applied to 34 eyes of 17 MGD patients with decreased BUT and dry-eye symptoms for 5 minutes once a day for 2 weeks. The 16 eyes of 8 patients served as untreated controls. We examined tear film lipid layer interference patterns, BUT, meibomian gland secretion, and dry-eye symptoms in both groups before and after the treatment. Results: BUT and dry-eye symptoms significantly improved after the treatment in both the short-term and the therapeutic study (P<.01). The incidence of normal tear lipid layer in the treated group was significantly higher after treatment (28 eyes [82.4{\%}]) than before (19 eyes [55.9{\%}]) (P=.036). The incidence of meibomian gland obstruction was significantly decreased after treatment (14 eyes [41.2{\%}]) compared to before treatment (26 eyes [76.5{\%}]) (P=.006). Conclusions: Warming the eyelids with the Eye Warmer improved the stability and uniformity of the tear lipid layer in MGD patients by melting the meibomian gland lipid. Our study demonstrates the usefulness of the Eye Warmer for the treatment of MGD.",
keywords = "Meibomian gland dysfunction, Tear film, Temperature, Warm compress",
author = "Asako Mori and Jun Shimazaki and Shigeto Shimmura and Hiroshi Fujishima and Yoshihisa Oguchi and Kazuo Tsubota",
year = "2003",
month = "11",
doi = "10.1016/S0021-5155(03)00142-4",
language = "English",
volume = "47",
pages = "578--586",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Disposable eyelid-warming device for the treatment of meibomian gland dysfunction

AU - Mori, Asako

AU - Shimazaki, Jun

AU - Shimmura, Shigeto

AU - Fujishima, Hiroshi

AU - Oguchi, Yoshihisa

AU - Tsubota, Kazuo

PY - 2003/11

Y1 - 2003/11

N2 - Purpose: To assess the clinical efficacy of a newly developed disposable eyelid-warming device (Eye Warmer) for the treatment of meibomian gland dysfunction (MGD). Methods: The Eye Warmer was applied for 5 minutes to 44 eyes of 22 patients who exhibited decreased tear break-up time (BUT) and dry-eye symptoms. Its efficacy was assessed on the basis of BUT and dry-eye symptoms in the short-term study. In the therapeutic study, the Eye Warmer was applied to 34 eyes of 17 MGD patients with decreased BUT and dry-eye symptoms for 5 minutes once a day for 2 weeks. The 16 eyes of 8 patients served as untreated controls. We examined tear film lipid layer interference patterns, BUT, meibomian gland secretion, and dry-eye symptoms in both groups before and after the treatment. Results: BUT and dry-eye symptoms significantly improved after the treatment in both the short-term and the therapeutic study (P<.01). The incidence of normal tear lipid layer in the treated group was significantly higher after treatment (28 eyes [82.4%]) than before (19 eyes [55.9%]) (P=.036). The incidence of meibomian gland obstruction was significantly decreased after treatment (14 eyes [41.2%]) compared to before treatment (26 eyes [76.5%]) (P=.006). Conclusions: Warming the eyelids with the Eye Warmer improved the stability and uniformity of the tear lipid layer in MGD patients by melting the meibomian gland lipid. Our study demonstrates the usefulness of the Eye Warmer for the treatment of MGD.

AB - Purpose: To assess the clinical efficacy of a newly developed disposable eyelid-warming device (Eye Warmer) for the treatment of meibomian gland dysfunction (MGD). Methods: The Eye Warmer was applied for 5 minutes to 44 eyes of 22 patients who exhibited decreased tear break-up time (BUT) and dry-eye symptoms. Its efficacy was assessed on the basis of BUT and dry-eye symptoms in the short-term study. In the therapeutic study, the Eye Warmer was applied to 34 eyes of 17 MGD patients with decreased BUT and dry-eye symptoms for 5 minutes once a day for 2 weeks. The 16 eyes of 8 patients served as untreated controls. We examined tear film lipid layer interference patterns, BUT, meibomian gland secretion, and dry-eye symptoms in both groups before and after the treatment. Results: BUT and dry-eye symptoms significantly improved after the treatment in both the short-term and the therapeutic study (P<.01). The incidence of normal tear lipid layer in the treated group was significantly higher after treatment (28 eyes [82.4%]) than before (19 eyes [55.9%]) (P=.036). The incidence of meibomian gland obstruction was significantly decreased after treatment (14 eyes [41.2%]) compared to before treatment (26 eyes [76.5%]) (P=.006). Conclusions: Warming the eyelids with the Eye Warmer improved the stability and uniformity of the tear lipid layer in MGD patients by melting the meibomian gland lipid. Our study demonstrates the usefulness of the Eye Warmer for the treatment of MGD.

KW - Meibomian gland dysfunction

KW - Tear film

KW - Temperature

KW - Warm compress

UR - http://www.scopus.com/inward/record.url?scp=0242551335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242551335&partnerID=8YFLogxK

U2 - 10.1016/S0021-5155(03)00142-4

DO - 10.1016/S0021-5155(03)00142-4

M3 - Article

VL - 47

SP - 578

EP - 586

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 6

ER -